Company Profile
Corbus Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- CRBP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.08 USD (-0.98%)
Close
Last updated: July 27, 2026
140M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, CRBP closed down 0.98% at $9.08. No new same-company headline was identified in the current news window.
Company overview
Business overview
Corbus Pharmaceuticals is a biotechnology company focused on inflammation, oncology, and endocannabinoid biology. Its story is built around a narrow set of clinical programs and strategic repositioning.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Corbus sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical data, target selection, and the ability to create a differentiated pipeline in immune disease and cancer.
Position Within the Biotechnology Landscape
Corbus is a small-cap catalyst name whose valuation is heavily dependent on program progress.
Future catalysts
Corbus’s catalysts are CRB-701 and CRB-913, with oncology and obesity updates doing most of the work. The company will be judged on whether its next data can support a larger development step.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Corbus Pharmaceuticals (CRBP)?
Corbus Pharmaceuticals (CRBP) most recently closed at 9.08 USD, a -0.98% move versus the previous session.
What is the market cap of Corbus Pharmaceuticals (CRBP)?
Corbus Pharmaceuticals currently has a market capitalization of 140M USD on BioPharmSignal.
What does Corbus Pharmaceuticals do?
Corbus Pharmaceuticals is a biotechnology company focused on inflammation, oncology, and endocannabinoid biology. Its story is built around a narrow set of clinical programs and strategic repositioning.
On which exchange is CRBP stock listed?
Corbus Pharmaceuticals (CRBP) is associated with NASDAQ, United States, Biopharma.
What is CRB-701?
Corbus’s catalysts are CRB-701 and CRB-913, with oncology and obesity updates doing most of the work.
Which conditions is Corbus Pharmaceuticals targeting with CRB-701?
Corbus Pharmaceuticals is associated with oncology, inflammatory disease, obesity based on its company overview and current catalyst commentary.
How does Corbus Pharmaceuticals describe recent progress with CRB-701?
Corbus’s catalysts are CRB-701 and CRB-913, with oncology and obesity updates doing most of the work.
What is CRB-913?
Corbus’s catalysts are CRB-701 and CRB-913, with oncology and obesity updates doing most of the work.